Skip to main content Accessibility help
×
Home

Prospective monitoring of carbapenem use and pseudomonal resistance across pediatric institutions

  • Isao Miyairi (a1), Kensuke Shoji (a1), Noriko Kinoshita (a1), Junpei Saitoh (a2), Yoshie Sugahara (a3), Yasushi Watanabe (a4), Makoto Komura (a2), Masashi Kasai (a5), Yuho Horikoshi (a6), Masayoshi Shinjoh (a7) and Takashi Igarashi (a8)...

Abstract

Objective:

To determine whether carbapenem consumption and Pseudomonas aeruginosa resistance rates can be used as benchmarks to compare and improve antimicrobial stewardship programs across multiple pediatric hospitals.

Design:

A prospective study.

Setting and participants:

Healthcare institutions in Japan with >100 pediatric beds.

Methods:

An annual survey of the total days of therapy (DOT) per 1,000 patient days for carbapenem antibiotics (meropenem, imipenem-cilastatin, panipenem-betamipron, doripenem) and susceptibility rates of Pseudomonas aeruginosa to meropenem and imipenem-cilastatin from each institution was conducted over a 7-year period. Data were reported to the administration, as well as to the infection control team, of each institution annually.

Results:

Data were obtained from 32 facilities. The median total carbapenem DOT per 1,000 patient days was 16.6 and varied widely, with a range of 2.7 to 59.0. The median susceptibility to meropenem was 86.6%, ranging from 78.6% to 96.6%. We detected an inverse correlation between total carbapenem DOT versus susceptibility (r = – 0.36; P < .01). Over the 7-year period, the DOT per 1,000 patient days of carbapenem decreased by 27% from a median of 16.0 to 11.7 (P < .01). We also observed an improvement in susceptibility to meropenem from a median of 87% to 89.7% (P = .01) and to imipenem-cilastatin from 79% to 85% (P < .01). The decreases in the use of carbapenem were greater in institutions with antimicrobial stewardship programs led by pediatric infectious disease specialists.

Conclusions:

Antimicrobial use and resistance, targeting carbapenems and P. aeruginosa, respectively, can serve as benchmarks that can be utilized to promote antimicrobial stewardship across pediatric healthcare institutions.

Copyright

Corresponding author

Author for correspondence: Isao Miyairi, E-mail: miyairi-i@ncchd.go.jp

References

Hide All
1.The Government of Japan. National Action Plan on Antimicrobial Resistance (AMR) 2016–2020. Tokyo: Government of Japan; 2016.
2.Horikoshi, Y, Suwa, J, Higuchi, H, et al.Sustained pediatric antimicrobial stewardship program with consultation to infectious diseases reduced carbapenem resistance and infection-related mortality. Int J Infect Dis 2017;64:6973.
3.Pluss-Suard, C, Pannatier, A, Kronenberg, A, Muhlemann, K, Zanetti, G. Impact of antibiotic use on carbapenem resistance in Pseudomonas aeruginosa: is there a role for antibiotic diversity? Antimicrob Agents Chemother 2013;57:17091713.
4.Newland, JG, Gerber, JS, Kronman, MP, et al.Sharing Antimicrobial Reports for Pediatric Stewardship (SHARPS): a quality improvement collaborative. J Pediatr Infect Dis Soc 2018;7:124128.
5.Hersh, AL, De Lurgio, SA, Thurm, C, et al.Antimicrobial stewardship programs in freestanding children’s hospitals. Pediatrics 2015;135:3339.
6.Smith, MJ, Gerber, JS, Hersh, AL. inpatient antimicrobial stewardship in pediatrics: a systematic review. J Pediatr Infect Dis Soc 2015;4:e127e135.
7.Patel, SV, Vergnano, S. The impact of paediatric antimicrobial stewardship programmes on patient outcomes. Curr Opin Infect Dis 2018;31:216223.
8.Araujo da Silva, AR, Albernaz de Almeida Dias, DC, Marques, AF, et al.Role of antimicrobial stewardship programmes in children: a systematic review. J Hosp Infect 2018;99:117123.
9.Polk, RE, Fox, C, Mahoney, A, Letcavage, J, MacDougall, C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007;44:664670.
10.Coffin, SE, Lee, GM. Mind the gap: spanning the great divide between perceived and measured value of infectious disease physicians. J Pediatr Infect Dis Soc 2019;8:276278.
11.Schuster, JE, Newland, JG. An enterovirus D68 outbreak highlights the value of pediatric infectious disease specialists. J Pediatr Infect Dis Soc 2015;4:8788.
12.Furuichi, M, Furuichi, M, Horikoshi, Y, Miyairi, I. Infectious diseases consultation improves treatment and decreases mortality by enterococcal bacteremia in children. Pediatr Infect Dis J 2018;37:856860.
13.Mano, Y, Saga, T, Ishii, Y, et al.Molecular analysis of the integrons of metallo-beta-lactamase–producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan. BMC Microbiol 2015;15:41.
14.D’Agata, E. Pseudomonas aeruginosa and other Pseudomonas species. In: Bennett, JE, Dolin, R, Blaser, MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, eighth edition. Philadelphia: Saunders; 2015. Pp. 25182538.
15.Gravatt, LA, Pakyz, AL. Challenges in measuring antibiotic consumption. Curr Infect Dis Rept 2013;15:559563.
16.Guidelines for ATC classification and DDD assignment 2018. WHO Collaborating Centre for Drug Statistics Methodology website. https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/. Updated December 12, 2019. Accessed May 18, 2020.
17.Pakyz, AL, Gurgle, HE, Ibrahim, OM, Oinonen, MJ, Polk, RE. Trends in antibacterial use in hospitalized pediatric patients in United States academic health centers. Infect Control Hosp Epidemiol 2009;30:600603.
Type Description Title
UNKNOWN
Supplementary materials

Miyairi et al. supplementary material
Figure S1

 Unknown (1.5 MB)
1.5 MB
UNKNOWN
Supplementary materials

Miyairi et al. supplementary material
Figure S2

 Unknown (3.5 MB)
3.5 MB

Prospective monitoring of carbapenem use and pseudomonal resistance across pediatric institutions

  • Isao Miyairi (a1), Kensuke Shoji (a1), Noriko Kinoshita (a1), Junpei Saitoh (a2), Yoshie Sugahara (a3), Yasushi Watanabe (a4), Makoto Komura (a2), Masashi Kasai (a5), Yuho Horikoshi (a6), Masayoshi Shinjoh (a7) and Takashi Igarashi (a8)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.